Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Roche to pay €130mm up front for cervical cancer diagnostics developer mtm

19 Aug 2011

Executive Summary

Roche is paying €130mm up front ($180mm) and up to €60mm in performance-related earn-outs for private cervical cancer testing company mtm Laboratories AG, which will become a division of the Big Pharma’s tissue-based diagnostics unit Ventana Medical Systems Inc. (part of Roche Diagnostics).
Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Cytology
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By